What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “\[Ac225\]RTX-2358 will be given as an intravenous injection once every 8 weeks for up to 6 doses. Each group will receive a set administered activity level (dose) of \[Ac 225\]RTX 2358 given once every 8 weeks. The first group will received the lower dose, the second group will received the mid level dose, and the third group the highest dose. A Safety Review Committee will determine when/if it…”In the company’s words, NCT07156565 on ClinicalTrials.gov
- Tested for
- Advanced Soft Tissue Sarcoma
- Main trialPhase 1
- “The goal of this clinical trial is to learn about the safety of drug \[Ac225\]RTX-2358 and the diagnostic imaging agent \[Cu64\]LNTH-1363S. Additionally Ratio Therapeutics will learn if \[Ac225\]RTX-2358 drug is effective in treating advanced sarcoma. The main questions the study aims to answer in Phase/Part 1 of the trial are: * Is \[Ac225\]RTX-2358 tolerable or does it cause toxicities (medical problems) in patients. * What is the most tolerable dose of \[Ac225\]RTX-2358 * Does the treatment show effectiveness on advanced sarcoma Participants will: * Take drug \[Ac225\]RTX-2358 once…”In the company’s words, NCT07156565 on ClinicalTrials.gov
Other drugs for Advanced Soft Tissue Sarcoma
Coming up1
- Jan 2028Phase 1 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 9 NovStatus changed: Recruiting to Active, not recruiting · ClinicalTrials.gov NCT07156565
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Active, not recruiting | Jan 2028 | Actinium Therapy for Late-stage Aggressive Sarcomas |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026